

RESEARCH ADVISORY PANEL OF CALIFORNIA

<https://oag.ca.gov/research>

MEETING NOTICE & AGENDA

The Research Advisory Panel of California (“RAPC”) will hold a public meeting at the following date and time at the location identified below and via video and telephone conference:

Date: Friday, July 19, 2024

Time: 12:30 pm PDT

NOTE: Please be advised, in accordance with Health and Safety Code section 11480.5, subd. (a), as added by California Assembly Bill (AB) 2841 (Waldron) (2024), and Government Code section 11123.5, RAPC will conduct this meeting by videoconference and teleconference. Every participating member of RAPC will attend this meeting remotely by videoconference. Members of the public may attend this meeting by teleconference, videoconference, or at the primary physical location, as described below.

To join by videoconference:

<https://doj-ca.zoomgov.com/j/1605311071>

To join by teleconference:

Dial: 669 254 5252

Webinar ID: 160 531 1071

Primary physical location:

California Department of Justice

4949 Broadway, Room G102

Sacramento, CA 95820

NOTE: Please be advised that Zoom may require attendees to input a name and an email address in order to attend a videoconference. You may use a pseudonym and a pseudonymous email if you would prefer not to use your name. You may also attend by telephone without giving a name (though your phone number will be visible to the panelists and RAPC staff).

MEETING AGENDA

OPEN SESSION

1. Call to Order and Establishment of a Quorum
2. Introduction of RAPC members
3. Selection of a new RAPC Chairperson
4. Bagley-Keene Open Meeting Act Training by Attorney General's Office
5. Discussion of process for preliminary review of research projects
6. Discuss backlog of pending applications and prioritization

CLOSED SESSION

7. Review and possible approval of proposed studies involving controlled substances

Closed session pursuant to Government Code section 11126, subd. (c)(20), as added by California AB 2841 (Waldron) (2024) – *Discussion, review, and potential approval of twenty-eight proposed human research projects into the nature and effects of cannabis or hallucinogenic drugs or substance use disorder treatment. Each proposed research project is under preliminary review by a RAPC subcommittee and contains sensitive and confidential information the public disclosure of which is prohibited by law.*

- a) Application No. PR#202304C. Applicant's Institution: UCLA
- b) Application No. PR#202320H. Applicant's Institution: UCLA
- c) Application No. PR#202321C. Applicant: Beckley-Psytech
- d) Application No. PR#202323H. Applicant's Institution: Stanford
- e) Application No. PR#202324H. Applicant's Institution: UCSF
- f) Application No. PR#202328H. Applicant's Institution: UCLA
- g) Application No. PR#202330S. Applicant's Institution: UCLA
- h) Application No. PR#202333S. Applicant: Cari Health
- i) Application No. PR#202335H. Applicant's Institution: UCLA
- j) Application No. PR#202336H. Applicant's Institution: UCSF
- k) Application No. PR#202337H. Applicant's Institution: UCSF
- l) Application No. PR#202338S. Applicant: NIDA/Yale
- m) Application No. PR#202339C. Applicant: Relmada Therapeutics
- n) Application No. PR#202341H. Applicant's Institution: UCLA
- o) Application No. PR#202344H. Applicant's Institution: VA San Diego
- p) Application No. PR#202347H. Applicant's Institution: UCSF
- q) Application No. PR#202348S. Applicant's Institution: NIDA/UCLA
- r) Application No. PR#202402H. Applicant's Institution: UCSF
- s) Application No. PR#202403C. Applicant: Usona Institute
- t) Application No. PR#202405S. Applicant: NIDA
- u) Application No. PR#202407H. Applicant's Institution: VA Los Angeles
- v) Application No. PR#202408S. Applicant: NIDA/Icahn Mount Sinai
- w) Application No. PR#202411H. Applicant's Institution: University of British Columbia
- x) Application No. PR#202412C. Applicant: Hound Labs
- y) Application No. PR#202413C. Applicant: Hound Labs
- z) Application No. PR#202414C. Applicant: Hound Labs
- aa) Application No. PR#202417H. Applicant: Pacific Neuroscience institute
- bb) Application No. PR#202418H. Applicant's Institution: UC Berkeley

8. Review and possible approval of proposed studies involving controlled substances

Closed session pursuant to Government Code section 11126, subd. (c)(20), as added by California AB 2841 (Waldron) (2024) – *Discussion, review, and potential approval of fifteen proposed non-human research projects into the nature and effects of cannabis or hallucinogenic drugs. Each proposed research project is under preliminary review by a RAPC subcommittee and contains sensitive and confidential information the public disclosure of which is prohibited by law.*

- a) Application No. PR#202326N. Applicant: Herophilus
- b) Application No. PR#202332N. Applicant's Institution: UCLA
- c) Application No. PR#202334N. Applicant's Institution: UC Irvine
- d) Application No. PR#202340N. Applicant's Institution: UC Irvine
- e) Application No. PR#202342N. Applicant's Institution: Lawrence Berkeley National Lab
- f) Application No. PR#202343N. Applicant's Institution: UCSD
- g) Application No. PR#202345N. Applicant's Institution: UC Irvine
- h) Application No. PR#202349N. Applicant's Institution: Stanford
- i) Application No. PR#202401N. Applicant's Institution: UC Merced
- j) Application No. PR#202404N. Applicant's Institution: UC Davis
- k) Application No. PR#202406N. Applicant's Institution: UCSD
- l) Application No. PR#202409N. Applicant: S&B Pharma
- m) Application No. PR#202410N. Applicant's Institution: Loma Linda University
- n) Application No. PR#202415N. Applicant: Sanford Benham Prebys Medical Discovery Institute
- o) Application No. PR#202416X – Applicant: Reunion Neuroscience

9. Review and possible approval of proposed studies involving controlled substances

Closed session pursuant to Government Code section 11126, subd. (c)(20), as added by California AB 2841 (Waldron) (2024) – *Discussion, review, and potential approval of sixteen amended human research projects into the nature and effects of cannabis or hallucinogenic drugs or substance use disorder treatment. Each proposed research project is under preliminary review by a RAPC subcommittee and contains sensitive and confidential information the public disclosure of which is prohibited by law.*

- a) Application No. PR#202110H. Applicant's Institution: UCSD
- b) Application No. PR#202115H. Applicant's Institution: UCSF
- c) Application No. PR#202302C. Applicant: Skye Bioscience
- d) Application No. PR#1927S. Applicant's Institution: NIDA
- e) Application No. PR#1843S. Applicant's Institution: UCLA
- f) Application No. PR#202019H. Applicant's Institution: UCSD
- g) Application No. PR#202220H. Applicant's Institution: UCLA
- h) Application No. PR#202303H. Applicant's Institution: VA San Diego
- i) Application No. PR#202239HC. Applicant's Institution: UCSD
- j) Application No. PR#202021H. Applicant's Institution: UCLA
- k) Application No. PR#202243C. Applicant: Compass Pathfinder
- l) Application No. PR#202116H. Applicant's Institution: UCSF
- m) Application No. PR#202143H. Applicant's Institution: UCSF
- n) Application No. PR#202117C. Applicant: RELMADA Therapeutics
- o) Application No. PR#202112H. Applicant's Institution: UCSF

p) Application No. PR#1916H . Applicant's Institution: Stanford

10. Review and possible approval of proposed studies involving controlled substances

Closed session pursuant to Government Code section 11126, subd. (c)(20), as added by California AB 2841 (Waldron) (2024) – *Discussion, review, and potential approval of four amended non-human research projects into the nature and effects of cannabis or hallucinogenic drugs. Each proposed research project is under preliminary review by a RAPC subcommittee and contains sensitive and confidential information the public disclosure of which is prohibited by law.*

- a) Application No. PR#202113N. Applicant: Lyfe Chng
- b) Application No. PR#202203N. Applicant's Institution: UCSD
- c) Application No. PR#2009Nx. Applicant's Institution: UCSD
- d) Application No. PR#202228N. Applicant: Alexander Shulgin Research Institute

OPEN SESSION

11. Adjournment

NOTICE TO THE PUBLIC

Agenda items may be discussed and actions taken out of order at the discretion of the Chairperson for convenience, to accommodate speakers, and to maintain a quorum. Action may be taken on any item on the agenda.

Public Comment: Members of the public who are attending will be given the opportunity to make comments on each agenda item prior to any action. If public comment is not specifically requested, members of the public should feel free to request an opportunity to comment. Total time allocated for public comment may be limited. Comments will be limited to three minutes per person; however, the Chairperson may decide to shorten or lengthen the public comment period at his or her discretion. Members of the public will not be permitted to "yield" their allotted time to other members of the public to make comments.

Accessibility: RAPC complies with the Americans with Disabilities Act by ensuring that the meeting facilities are accessible to persons with disabilities, and providing that this notice and information given to the members of RAPC is available to the public in appropriate alternative formats when requested. If you need assistance, including disability-related modifications or accommodations to participate in this meeting, please make your request by contacting RAPC Executive Officer Tanveer Khan at (916) 210-5382, RAPC@doj.ca.gov, or 4949 Broadway, Sacramento, CA 95820. Requests must be received at least five business days before the meeting to ensure availability of the requested accommodation.

For the meeting notice and agenda and more information, please access RAPC's website at <https://oag.ca.gov/research>. Please direct requests for further information to RAPC Executive Officer Tanveer Khan, at (916) 210-5382, RAPC@doj.ca.gov, 4949 Broadway, Sacramento, CA 95820

More information regarding research studies reviewed by RAPC in 2022 can be found at <https://oag.ca.gov/system/files/media/52nd-annual-report-2022.pdf>.